Lycopodium Ltd

(LYL \$5.20) Buy

Analyst Date Price Target
Harry Stevenson March 2021 \$6.62/sh

Half Year Results

Investment case

Lycopodium has recently released half year results which were inline with expectations. With completion of Yaoure in December margins remained strong with NPAT at 8.8%. With full year guidance of "approximately \$160m in revenue and NPAT in the order of \$12m" our focus is increasingly shifting towards FY'22. We are looking towards an emerging EPCM/EPC boom with the with roll out of covid-19 vaccines globally, we expect projects which were previously delayed to be greenlit. This outlook is supported by strong gold prices and record iron ore demand which we expect to continue through FY'22. In the background Lycopodium's JV with Monodelphous – Mondium looks set for a further growth through FY'22 with completion of the Western Turner Syncline; which should drive stronger margins. Our price target reflects our growing confidence in the EPCM outlook.

Key points

Lycopodium recently reported half year results, key highlights were as follows

- Revenue of \$71m, EBITDA of \$10.6m and NPAT of \$6.3m (EHSL \$5.7m).
- Margins were heathy 8.9% at the NPAT level and towards the top end of historical rates between 5%-10%.
- Balance sheet remains strong; cash of \$84.4m and net assets of \$82.1m.
- Negative operating cash flows of \$15.7m expected given build-up of working capital at 30 June, we look for cash balance to normalise to ~\$67m at full year.
- A fully franked Dividend of 10c per share declared (ESHL 9.3c); we now look for 20c full year distribution.
- Contribution from Mondium (LYL's 40% JV with Monadelphous) up 15% HonH and 155% on PCP, we expect this contribution to become more meaningful through FY'22 (\$4.2m).
- Management have provided full year earnings guidance of "approximately \$160m in revenue and NPAT in the order of \$12m" - in line with our previous FY'21 forecasts of \$160m Revenue and NPAT of \$11.7m.

Outlook

- Demand for EPC/EPCM contractors through FY'21 and into FY'22 is expected to strengthen with the resources sector set to continue to benefit from both the Gold and Iron Ore prices.
- 12 month Price Target of \$6.62 is a 9x multiple on FY'22 EBIT forecasts.

EURØZ HARTLEYS

Lycopodium Ltd	Year End 30 June		
Share Price	5.20 A\$/sh		
Price Target Valuation (DCF) WACC Terminal Growth	6.62 A\$/sh 6.62 A\$/sh 9.0% 3.0%		
Shares on issue Market Capitalisation Enterprise Value Cash Debt	40 m, diluted 206.6 A\$m 137.6 A\$m 84.5 A\$m 15.5 A\$m		
Key Financials 2020a	2021f 2022		
Revenue (A\$m) 209.6 EBITDA (A\$m) 25.6 EBIT (A\$m) 17.5 Reported NPAT (A\$m) 11.7 Normalised NPAT (A\$m) 12.9	21.6 26.3 16.9 21.7 12.0 15.2		
Gross Cashflow (A\$m) 11.8 Capex (A\$m)* -0.6 Op. Free Cashflow (A\$m) 54.2	-1.0 -0.9		
Revenue Growth (%) 38% EBITDA Growth (%) 10% Norm. NPAT margin (%) 6%	-15% 22%		
Normalised EPS (Ac) 29.22 Norm. EPS growth (%) -29% PER (x) 17.7 EV:EBITDA (x) 4.2 EV:EBIT (x) 6.1	3% 26% 7 17.2 13.6 2 5.0 4.1		
DPS (Ac) 20.0 Dividend Yield (%) 3.8%			
Net cash (A\$m)* 99.2 Net Debt:Equity (%) Net cash Interest Cover (x) NA	Net cash Net cash		

Share Price Chart



Disclaimer

ASX Limited ABN 98 009 642 691 and its related bodies corporate ("ASX") did not prepare any part of the report and has not contributed in any way to its content. The role of ASX in relation to the preparation of this research report is limited to funding its preparation, by Euroz Hartleys Securities Limited in accordance with the ASX Faulty Research Scheme

Equity Research Scheme.
ASX does not provide financial product advice.
The views expressed in this research report
may not necessarily reflect the views of ASX.
To the maximum extent permitted by law, no
representation, warranty or undertaking, express
or implied, is made and no responsibility or
liability is accepted by ASX as to the adequacy,
accuracy, completeness or reasonableness of the
research report.

Lycopodium Ltd

(LYL \$5.20) Buy

EURØZ HARTLEYS

Financial Statements	2019a	2020a	2021f	2022f
Income Statement				
Revenue	152.2	209.6	160.0	200.0
OPEX FRIEDA	-129.0	-184.0	-138.4	-173.7
EBITDA Depreciation & amortisation	23.3 -1.5	25.6 -8.0	21.6 -4.8	26.3 -4.6
FBIT	21.8	-8.0 17.5	-4.8 16.9	-4.6 21.7
Net finace income	1.7	0.9	0.3	0.0
EBT	23.5	18.5	17.1	21.7
Tax expense	-7.1	-6.8	-5.1	-6.5
Reported Earnings	16.4	11.7	12.0	15.2
Abnormal Expeses / (Incomes)	0.2	1.2	0.0	0.0
Normalized Net Profit	16.6	12.9	12.0	15.2
Cash flow (A\$m)	2019a	2020a	2021f	2022f
Profit before Tax	16.4	11.7	12.0	15.2
(+) D&A	1.5	8.0	4.8	4.6
(-) Lease Expense	0.0	-5.6	-3.4	-3.4
(+/-) Impairements, Non-cash	0.0	0.0	0.0	0.0
(+/-) FX	-13.4	-0.7	0.0	0.0
(+/-) Other Gross Cashflow	0.0 4.5	-1.6 11.8	0.0 13.4	0.0 16.4
(-) Capital Expenditure	-1.6	-0.6	-1.0	-0.9
(-) Change in WC	-18.4	43.0	-40.2	6.6
Operating Free cashflow	-15.5	54.2	-27.8	22.2
(-) Dividend Paid	-13.1	-11.9	-7.9	-9.9
(-/+) Proceeds from Disposals	0.0	0.0	0.0	0.0
(-) Investments	-3.4	0.0	0.0	0.0
(+/-) Other	18.7	0.4	0.0	0.0
Net Cashflow	-13.3	42.7	-35.7	12.3
Bop Net Cash	73.0	59.7 42.7	99.2	55.1
(+/-) Net Cashflow	-13.3 0.0	42.7 -3.2	-35.7 -8.4	12.3 0.0
(+/-) Lease Adjustment EoP Net Cash	59.7	99.2	-0.4 55.1	67.3
Balance Sheet (\$m)	2019a	2020a	2021f	2022f
Cash	60.5	102.9	67.3	79.6
Receivables	34.4	26.9	23.6	25.7
Contract and other assets	1.5	0.0	0.0	0.0
Inventories Current Tax Receivables	0.9 1.8	1.1 0.9	1.0 0.7	1.4
Other Current Assets	3.8	2.5	2.5	0.8 2.5
Derivative Financial Assets	0.0	0.0	0.0	0.0
Total Current Assets	102.8	134.3	95.1	110.0
Equity Accrted Investments	1.4	3.5	3.5	3.5
Investments in listed equities	0.8	0.9	0.9	0.9
Financial Assets avail for Sale	0.0	0.0	0.0	0.0
PP&E	3.8	3.2	2.9	2.8
Right of Use Asset	0.0	3.0	11.3	11.3
Intangible Assets	6.7	6.8	6.8	6.7
Other receivables	0.2	0.1	0.1	0.1
Deferred tax assets	4.1	3.8	3.8	3.8
Total Non-Current Assets	17.0	21.4	29.4	29.1
Total Assets	119.9	155.7	124.4	139.1
Payables	21.9	23.2	14.4	6.8
Contract and other liabilities	13.8	47.7	13.4	29.6
Borrowing	0.4	0.3	0.3	0.3
Lease Liabilties	0.0	1.6	6.5	6.5
Derivative financial liabiltiles Current tax liabilities	0.2 0.5	0.0 0.8	0.0 0.6	0.0 0.8
Provisions	3.0	2.3	1.7	2.2
Total Current Liabilities	39.8	75.9	37.0	46.2
Borrowings	0.3	0.2	0.2	0.2
Provisions	0.3	0.1	0.1	0.1
Lease Liabiltiies	0.0	1.6	5.2	5.2
Total Non-Current Liabilities	0.6	1.9	5.5	5.5
Total Liabilities	40.4	77.8	42.5	51.8
Net Assets	79.4	77.8	81.9	87.2
Issued capital	20.8	20.8	20.8	20.8
Reserves	-0.6	-1.8	-1.8	-1.8
Retained profits	59.6	59.5	63.6	68.9
NCI	-0.4	-0.7	-0.7	-0.7
Total Equity	79.4	77.8	81.9	87.2

Performance Ratios	2019a	2020a	2021f	2022f
Growth & Margins				
Revenue Growth	-21%	38%	-24%	25%
EBITDA Growth	-8%	10%	-15%	22%
EBITDA margin	15%	12%	14%	13%
EBIT margin	14%	8%	11%	11%
EBIT Growth	-9%	-20%	-4%	29%
Normalized net profit margin	11%	6%	8%	8%
Effective tax rate	30%	30%	30%	30%
	3070	3070	3070	3070
Liquidity				
Capex/depreciation (x)	1.1	0.1	0.2	0.2
Current ratio (x)	2.6	1.8	2.6	2.4
Quick ratio (x)	226.2	426.8	298.9	346.0
Receivable days	82	47	54	47
Payable days	70	62	42	17
Risk Measures				
Dividend Cover (x)	1.3	1.0	1.5	1.5
Payout ratio (%)	73%	68%	66%	65%
Net interest cover (x)	na	na	na	na
Net debt/equity (%)	net cash i	iet casn i	iet casnin	iet casn
Returns				
ROIC(%)	19%	15%	12%	15%
Return on assets (%)	14%	8%	10%	11%
Return on average equity (%)	21%	15%	15%	17%
Share Data/Valuation	2019a	2020a	2021f	2022f
Share Data				
Issued shares (m)	39.7	39.7	39.7	39.7
Weighted ave shares (m)	39.7	39.7	39.7	39.7
Fully diluted shares (m)	39.7	40.0	40.0	40.0
Basic EPS (c)	41.3	29.4	30.2	38.2
YoY change (%)	-12%	-29%	3%	26%
Fully diluted EPS (c)	41.3	29.2	30.0	38.0
YoY change (%)	-12%	-29%	3%	26%
Fully diluted normalised EPS (c)	41.3	29.2	30.0	38.0
YoY change (%)	-12%	-29%	3%	26%
Dividend/share (c)	30.0	20.0	19.9	24.8
Franking (%)	100%	100%	100%	100%
Gross cashflow/share (c)	11.3	29.7	33.7	41.3
NBV/share (c)	199.9	195.9	206.2	219.8
NTA/Share (c)	182.9	177.7	188.0	201.7
Valuation				
PER (Basic) (x)	12.6	17.7	17.2	13.6
PER (Fully diluted) (x)	12.6	17.8	17.3	13.7
PER (Fully diluted, normalized) (x)	12.6	17.7	17.2	13.6
P/CFPS (x)	46.0	17.5	15.4	12.6
Price/NBV (x)	2.6	2.7	2.5	2.4
Price/NTA (x)	2.8	2.9	2.8	2.6
market Cap (EOFY)	206.6	206.6	206.6	206.6
EV	146.9	107.4	107.4	107.4
EV/EBITDA (x)	15.8	4.2	5.0	4.1
EV/EDIT ()				
EV/EBII (X)	27.7	6.1	6.4	5.0
EV/Revenue (x)	0.4	0.1	0.2	0.2
Other Information				
Estimated free float				29%
			<i>C A</i>	
12-mth High/Low (A\$/sh)			0.4	0/3.70
Average daily volume (A\$'000s)				83
ACV C 1				13.77
ASX Code				LYL
Next result				Aug-21
Company Description				

Company Description

Lycopodium Limited (LYL) provides integrated engineering, construction and asset management solutions to global resource markets. Established in 1992 and listed on the ASX in 2004 the company has a 25-year track record of delivering EPCM/EPC contracting and engineering to services to a diverse range of industries.



Disclaimer

Copyright & Distribution

The material contained in this communication (and all attachments) is prepared for the exclusive use of clients of Euroz Hartleys Securities Ltd (ACN 089 314 983) and Euroz Hartleys Limited (ACN 104 195 057) only.

Euroz Hartleys Securities Limited is the holder of an Australian Financial Services Licence (AFSL 243302) and is a participant of the Australian Securities Exchange Group.

Euroz Hartleys Limited is the holder of an Australian Financial Services Licence (AFSL 230052) and is a participant of the Australian Securities Exchange Group.

The information contained herein is confidential. If you are not the intended recipient no confidentiality is lost by your receipt of it. Please delete and destroy all copies, and contact Euroz Hartleys Securities Limited on (+618) 9488 1400. You should not use, copy, disclose or distribute this information without the express written authority of Euroz Hartleys Securities Limited.

Disclaimer & Disclosure

Euroz Hartleys Securities Limited and Euroz Hartleys Limited, and their associates declare that they deal in securities as part of their securities business and consequently may have an interest in the securities recommended herein (if any). This may include providing equity capital market services to the issuing company, hold a position in the securities, trading as principal or agent and as such may effect transactions not consistent with the recommendation (if any) in this report.

Euroz Hartleys Securities Limited and Euroz Hartleys Limited declares that they may have separately or jointly acted as an underwriter, arranger, co-arranger or adviser in equity capital raisings, and will have received a fee for its services, from or any company mentioned within this report during the last 12 months.

You should not act on any recommendation issued by Euroz Hartleys Securities Limited without first consulting your investment adviser in order to ascertain whether the recommendation (if any) is appropriate, having regard to your objectives, financial situation and needs. Nothing in this report shall be construed as a solicitation to buy or sell a security, or to engage in or refrain from engaging in any transaction.

Euroz Hartleys Securities Limited believes that the information and advice contained herein is correct at the time of compilation, however we make no representation or warranty that it is accurate, complete, reliable or up to date, nor do we accept any obligation to correct or update the opinions in it. The opinions expressed are subject to change without notice. No member of Euroz Hartleys Securities Limited accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this material.

We cannot guarantee that the integrity of this communication has been maintained, is free from errors, virus interception or interference.

The author of this publication, Euroz Hartleys Securities Limited, and Euroz Hartleys Limited, it's directors and their associates from time to time may hold shares in the security/securities mentioned in this Research document and therefore may benefit from any increase in the price of those securities. Both Euroz Hartleys Securities Limited and Euroz Hartleys Limited, and its Advisers may earn brokerage, fees, commissions, other benefits or advantages as a result of transactions arising from any advice mentioned in publications to clients.

Analyst Certification

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities, and we are not in possession of, nor does this Research contain any inside information

No part of our compensation was, is or will be directly or indirectly, related to the specific recommendations or views expressed by the authoring analyst in this research, nor has any attempt been made to influence this Research.

Contact Details

Euroz Hartleys Securities Limited +61 8 9488 1400

Research Analysts

 Jon Bishop - Head of Research
 +61 8 9488 1481

 Mike Millikan - Resources Analyst
 +61 8 9268 2805

 Michael Scantlebury - Resources Analyst
 +61 8 9268 2837

 Steven Clark - Resources Analyst
 +61 8 9488 1430

 Trent Barnett - Senior Analyst
 +61 8 9268 3052

 Gavin Allen - Senior Analyst
 +61 8 9488 1413

 Harry Stevenson - Industrials Analyst
 +61 8 9488 1429

 Seth Lizee - Associate Research Analyst
 +61 8 9488 1414